NICE does not recommend Gilenya(Novartis) for Relapsing Remitting Multiple Sclerosis

The second appraisal consultation document from the National Institute of Clinical Evidence (NICE) provisionally does not recommend Gilenya (fingolimod) from Novartis for highly active relapsing-remitting Multiple Sclerosis; a type of the condition characterised by periods when symptoms worsen and then improve. The second draft has been published following a proposed discount from Novartis (called a Patient Access Scheme) to the price of fingolimod. NICE's independent appraisal committee has not been convinced that offering fingolimod would be a cost effective option for the NHS.